综述:肝硬化患者营养不良/肌少症与衰弱
该综述检索PubMed等数据库至2019年4月,汇总肝硬化营养不良/肌少症与衰弱的文献及国际指南。肝硬化中营养不良/肌少症患病率为23%-60%,衰弱常与之重叠,增加并发症和死亡;高氨血症可能是肌少症主要驱动因素;建议所有肝硬化患者快速营养筛查,高危者进一步评估肌少症,由多学科团队管理营养。
要点
- 肝硬化患者营养不良/肌少症患病率23%-60%,与不良结局相关。
- 所有肝硬化患者应快速营养筛查,高危者行肌少症专项评估。
- 营养管理由多学科团队实施,保证足量蛋白质/热量摄入。
核心结论
- 营养不良/肌少症和衰弱是肝硬化中独特、相互关联的多维问题,显著影响并发症和死亡,需特别关注、及时评估和适当管理。
研究设计与样本
- 综述:检索PubMed及其他来源,检索词包括sarcopenia、muscle、malnutrition、cirrhosis、liver和frailty,检索时限从建库至2019年4月,纳入相关研究和国际指南。
主要发现
- 肝硬化中营养不良/肌少症患病率为23%-60%。
- 衰弱通常与肝硬化中营养不良/肌少症重叠,导致并发症和死亡率增加。
- 肝硬化营养不良/肌少症发病机制复杂、多因素,不仅是蛋白质/热量摄入减少。
- 高氨血症似乎通过若干分子信号通路成为肝硬化肌少症的主要驱动因素。
关键数值与推荐
- 所有肝硬化患者应进行快速营养筛查评估,高危者应进行更具体的肌少症检测。
- 营养不良肝硬化患者的营养管理应由多学科团队实施,以达到足够的蛋白质/热量摄入。
- 支链氨基酸对降低死亡率和肝脏相关事件的全局获益仍有争议,但对晚期肝病患者推荐使用支链氨基酸和维生素补充剂。
临床怎么用
- 对所有肝硬化患者常规行快速营养筛查,高危者进一步评估肌少症。
- 由多学科团队管理营养不良肝硬化患者,保证足量蛋白质/热量摄入。
- 晚期肝病患者可考虑支链氨基酸和维生素补充剂。
局限性
- 本文为综述,检索截止2019年4月,未报告系统评价方法学细节。
- 逆转肌少症的新策略(激素补充、长期降氨药物、肌肉生长抑制素拮抗剂)仍在研究中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malnutrition/sarcopenia and frailty are common in patients with cirrhosis and are associated with poor outcomes. AIM: To provide an overview of data on the importance, assessment and management of malnutrition/sarcopenia and frailty in cirrhosis. METHODS: A literature search was conducted in PubMed and other sources, using the search terms "sarcopenia," "muscle," "malnutrition," "cirrhosis," "liver" and "frailty" from inception to April 2019, to identify the relevant studies and international guidelines. RESULTS: The prevalence of malnutrition/sarcopenia in cirrhosis is 23%-60%. Frailty generally overlaps with malnutrition/sarcopenia in cirrhosis, leading to increased morbidity and mortality. Rapid nutritional screening assessment should be performed in all patients with cirrhosis, and more specific tests for sarcopenia should be performed in those at high risk. The pathogenesis of malnutrition/sarcopenia in cirrhosis is complex/multifactorial and not just reduction in protein/calorie intake. Hyperammonemia appears to be the main driver of sarcopenia in cirrhosis through several molecular signalling pathways. Nutritional management in malnourished patients with cirrhosis should be undertaken by a multidisciplinary team to achieve adequate protein/calorie intake. While the role of branched-chained amino acids remains somewhat contentious in achieving a global benefit of decreasing mortality- and liver-related events, they, and vitamin supplements, are recommended for those with advanced liver disease. Novel strategies to reverse sarcopenia such as hormone supplementation, long-term ammonia-lowering agents and myostatin antagonists, are currently under investigation. CONCLUSIONS: Malnutrition/sarcopenia and frailty are unique, inter-related and multi-dimensional problems in cirrhosis which require special attention, prompt assessment and appropriate management as they significantly impact morbidity and mortality.
引用
- Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. Aliment Pharmacol Ther. 2019. PMID: 31701570. doi:10.1111/apt.15571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。